Navigation Links
Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
Date:4/17/2008

VANCOUVER, April 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its innovative 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) in the United States.

"The 5-FU CVC represents our first drug-eluting medical device product to be researched and developed completely in-house by Angiotech's R & D and clinical teams, without the aid of a corporate partner," said Dr. William Hunter, President and CEO of Angiotech. "This is an important milestone in our Company's history, and we look forward to moving into the commercial phase of our 5-FU CVC product, as well as developing other implantable devices that utilize this novel and proprietary anti-infective technology platform."

The clinical data from Angiotech's 960 patient clinical trial comparing its 5-FU CVC with a chlorhexidine/silver sulfadiazine (CH-SS) coated CVC was recently presented by clinical investigators at the 28th International Symposium on Intensive Care and Emergency Medicine in Brussels. The study met its primary non-inferiority endpoint and there were no occurrences of clinically evident blood stream infection in patients treated with Angiotech's 5-FU CVC.

About Angiotech's 5-FU CVC

Angiotech has demonstrated that 5-FU, a well-known and FDA approved drug, has effectively demonstrated its ability to prevent catheter-related infections as compared with CH-SS coated catheters. In addition, since 5-FU is not routinely used as either a systemic antibiotic or a hospital antiseptic, there may be a reduced risk to the hospital or the communi
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
2. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
3. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
4. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
5. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
6. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
7. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
8. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America
11. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 30, 2014 Whitehouse Laboratories ... its ICH Stability Testing and Package Test Capacity. Responding ... centers on a dramatic increase in environmental chamber storage ... stability, storage and aging samples to be securely held ... this major capital expenditure has already taken place with ...
(Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
(Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
(Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
... July 15 Amsterdam,Molecular Therapeutics (Euronext: AMT), a ... announced the start of a collaboration with St. ... the development,of a gene therapy treatment for Hemophilia ... commercial rights to the final product. The,combination of ...
... A report published in the July 8 issue of ... Sciences ( PNAS ) is the first to ... of tiny nanoclusters of metallic gold. The study, which ... the work of researchers at four universities on two ...
... HealthSonix, Inc.,(Pink Sheets: HSXI)(FWB:H7S) today announced that ... purchased two wholly owned,subsidiaries of HealthSonix, Inc. ... "Selling the two operating companies to Innovative ... the companies to,resume full operations and get ...
Cached Biology Technology:AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 2AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 3AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 4Study reveals principles behind stability and electronic properties of gold nanoclusters 2Study reveals principles behind stability and electronic properties of gold nanoclusters 3Study reveals principles behind stability and electronic properties of gold nanoclusters 4HealthSonix Sells Operating Subsidiaries to Innovative Health Sciences 2
(Date:10/29/2014)... the international Cancer Genomics of the Kidney consortium ... kidney cancer and exposure to aristolochic acid, an ... in Nature Communications , have important implications ... than 140,000 people every year, and in Central ... part of the International Cancer Genome Consortium (ICGC), ...
(Date:10/28/2014)... Scientists from North America, Europe and China have published ... Academy of Sciences that reveals important details about ... our planet., From strange and exotic algae, mosses, ferns, ... the grains and vegetables we eat and the ornamental ... shares over a billion years of history., "Our study ...
(Date:10/28/2014)... Technological University Singapore (NTU Singapore) will be building ... renewable energy sources. , The first in the ... the integration of solar, wind, tidal-current, diesel, storage ... operate well together. , To be built under ... initiative, the hybrid micro-grid will be located offshore ...
Breaking Biology News(10 mins):Kidney cancer in Central Europe 2New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
... condition that can appear after breast cancer surgery, ... survivors. Although lymphedema can cause lifelong swelling in ... no national standard of diagnosis or care. Now, ... Lymphedema Framework Project (ALFP), a national, multi-disciplinary collaboration ...
... Inc. has obtained a non-exclusive license to make ... developed at Case Western Reserve University,s Department of ... Center in Cleveland. The ... based in Indiana, Pa., rights to intramuscular recording ...
... Food packaging and other disposable plastic items could soon be ... new sugar-based polymer. The degradable polymer is made ... crops such as fast-growing trees and grasses, or renewable biomass ... at Imperial College London by a team of Engineering and ...
Cached Biology News:Researchers develop standard of care for breast cancer survivors with lymphedema 2Compostable plastics have a sweet ending 2
... Johnstone and M.W. Turner ... describes step-by-step methods for ... relevant molecules, the use ... specific analytical probes and ...
Request Info...
LabFax: Immunochemistry...
Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
Biology Products: